Insider Selling: ResMed (NYSE:RMD) Director Sells 2,000 Shares of Stock

Key Points

• Director Peter Farrell sold 2,000 shares on April 1 at an average price of $225, totaling $450,000, according to an SEC Form 4 filing.
• Strong quarterly results: ResMed reported EPS of $2.81 (vs. $2.68 consensus) and revenue of $1.42B, up 11% year‑over‑year, with a 27.5% net margin and analysts projecting about $9.47 EPS for the fiscal year.
• Market and payout snapshot: the stock traded around $223.48 (12‑month range $199.92–$293.81) with a $32.6B market cap, a $2.40 annual dividend (1.1% yield), and a consensus "Moderate Buy" target of $299.27.

ResMed Inc. (NYSE:RMD - Get Free Report) Director Peter Farrell sold 2,000 shares of the firm's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $225.00, for a total transaction of $450,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

ResMed Stock Performance

Shares of ResMed stock traded up $0.63 during midday trading on Thursday, hitting $223.48. The company had a trading volume of 316,792 shares, compared to its average volume of 1,085,771. The company has a quick ratio of 2.32, a current ratio of 3.06 and a debt-to-equity ratio of 0.06. The company has a fifty day simple moving average of $247.71 and a 200 day simple moving average of $253.95. ResMed Inc. has a 12-month low of $199.92 and a 12-month high of $293.81. The stock has a market cap of $32.56 billion, a price-to-earnings ratio of 22.10, a PEG ratio of 1.49 and a beta of 0.93.

ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings data on Friday, January 30th. The medical equipment provider reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.13. ResMed had a net margin of 27.53% and a return on equity of 25.20%. The firm had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same quarter in the prior year, the business earned $2.43 earnings per share. The business's quarterly revenue was up 11.0% compared to the same quarter last year. As a group, analysts predict that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 19th. Stockholders of record on Thursday, February 12th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend was Thursday, February 12th. ResMed's dividend payout ratio (DPR) is currently 23.74%.

Hedge Funds Weigh In On ResMed

Several large investors have recently bought and sold shares of the business. Jones Financial Companies Lllp raised its position in shares of ResMed by 52.6% during the 1st quarter. Jones Financial Companies Lllp now owns 2,882 shares of the medical equipment provider's stock worth $645,000 after acquiring an additional 994 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in ResMed by 7.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 5,316 shares of the medical equipment provider's stock valued at $1,372,000 after purchasing an additional 350 shares during the last quarter. Panagora Asset Management Inc. raised its holdings in ResMed by 1.0% during the second quarter. Panagora Asset Management Inc. now owns 6,661 shares of the medical equipment provider's stock worth $1,719,000 after purchasing an additional 63 shares in the last quarter. Shelton Capital Management purchased a new stake in shares of ResMed during the 2nd quarter worth approximately $214,000. Finally, Fisher Asset Management LLC lifted its position in shares of ResMed by 0.7% during the 2nd quarter. Fisher Asset Management LLC now owns 46,773 shares of the medical equipment provider's stock worth $12,068,000 after buying an additional 315 shares during the last quarter. Hedge funds and other institutional investors own 54.98% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on RMD. Stifel Nicolaus upped their price target on ResMed from $260.00 to $265.00 and gave the company a "hold" rating in a research note on Friday, January 30th. Royal Bank Of Canada boosted their price objective on ResMed from $311.00 to $314.00 and gave the company an "outperform" rating in a report on Friday, January 30th. Piper Sandler raised their target price on ResMed from $270.00 to $275.00 and gave the company a "neutral" rating in a report on Friday, January 30th. Weiss Ratings lowered shares of ResMed from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Thursday, March 19th. Finally, Robert W. Baird set a $281.00 price target on shares of ResMed in a research report on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, ResMed currently has a consensus rating of "Moderate Buy" and a consensus target price of $299.27.

About ResMed

ResMed NYSE: RMD is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.